Ansell (ANN) AGM 2024 summary

Opening remarks and agenda

• Chair welcomed attendees, acknowledged traditional land owners, and outlined meeting procedures for both in-person and virtual participants.

• Voting and question submission processes were explained, ensuring shareholder engagement and transparency.

• Quorum was confirmed, and the meeting was declared open with voting on all items commenced.

Financial performance review

• FY24 adjusted EPS was 105.5 US¢, within guidance; statutory EPS fell 46.3% to 59.4 US¢.

• FY24 sales reached $1,619.3m, down 2.9% in constant currency; GPADE margin improved to 31.9% (+150bps).

• Industrial segment achieved record EBIT margin, while healthcare segment saw improvement in the second half as destocking eased.

• Cash conversion rate was 131%, with operating cash flow at $167.9m and inventory reduced by $68m.

• Early FY25 trading showed strong organic sales growth in both industrial and healthcare segments, with revised EPS guidance of 110–127 US¢.

Strategic initiatives and plans

• Accelerated Productivity Investment Program delivered AUD 28m ($28m) in FY24 savings, targeting AUD 50m ($50m) annualised by FY26.

• KBU acquisition enhances growth in scientific verticals, expands product portfolio, and targets $10m run-rate cost synergies by year 3.

• Integration of KBU is progressing ahead of expectations, with full transition from Kimberly-Clark services expected by end of FY25.

• Organisational restructuring completed, including headcount reduction of ~90 executives and ~1,330 total staff, and streamlined executive team.

• IT digitisation strategy underway, with global ERP rollout planned to begin in FY26 and complete by FY27.